Insider Buying: Zenas BioPharma (NASDAQ:ZBIO) CEO Acquires 30,000 Shares of Stock

Zenas BioPharma, Inc. (NASDAQ:ZBIO) CEO Leon Moulder, Jr. purchased 30,000 shares of Zenas BioPharma stock in a transaction dated Thursday, January 8th. The shares were acquired at an average cost of $16.30 per share, with a total value of $489,000.00. Following the transaction, the chief executive officer directly owned 346,155 shares in the company, valued at approximately $5,642,326.50. The trade was a 9.49% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Zenas BioPharma Stock Performance

Shares of ZBIO traded down $0.33 on Friday, reaching $16.08. The company’s stock had a trading volume of 529,200 shares, compared to its average volume of 981,324. The stock’s 50 day simple moving average is $34.94 and its two-hundred day simple moving average is $24.01. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.66 and a quick ratio of 5.66. The stock has a market capitalization of $863.17 million, a P/E ratio of -2.27 and a beta of -1.45. Zenas BioPharma, Inc. has a 12-month low of $5.83 and a 12-month high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.35).

Institutional Trading of Zenas BioPharma

A number of hedge funds have recently added to or reduced their stakes in the business. Federated Hermes Inc. boosted its position in Zenas BioPharma by 60.8% during the 2nd quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock valued at $18,041,000 after acquiring an additional 703,838 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Zenas BioPharma by 17.2% in the third quarter. Vanguard Group Inc. now owns 1,162,758 shares of the company’s stock valued at $25,813,000 after purchasing an additional 170,546 shares during the period. Geode Capital Management LLC raised its position in shares of Zenas BioPharma by 4.6% in the second quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock valued at $3,621,000 after buying an additional 16,461 shares during the last quarter. Invesco Ltd. purchased a new position in Zenas BioPharma during the third quarter worth about $3,237,000. Finally, Millennium Management LLC purchased a new position in Zenas BioPharma during the third quarter worth about $1,595,000.

Analyst Ratings Changes

A number of research firms have weighed in on ZBIO. Wedbush reiterated an “outperform” rating and issued a $45.00 price target on shares of Zenas BioPharma in a research report on Monday, December 22nd. HC Wainwright reissued a “buy” rating on shares of Zenas BioPharma in a report on Tuesday, December 16th. Jefferies Financial Group restated a “buy” rating and issued a $48.00 price objective on shares of Zenas BioPharma in a research report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Monday, December 29th. Finally, Morgan Stanley downgraded Zenas BioPharma from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $37.00 to $19.00 in a research note on Monday. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Zenas BioPharma has an average rating of “Moderate Buy” and a consensus target price of $43.14.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.